Frontiers in Endocrinology (Apr 2024)

Diabetic peripheral neuropathy: age-stratified glycemic control

  • Chi-Sheng Wang,
  • Yen-Wei Pai,
  • Yen-Wei Pai,
  • Ching-Heng Lin,
  • I-Te Lee,
  • I-Te Lee,
  • Hsiao-Hui Chen,
  • Ming-Hong Chang,
  • Ming-Hong Chang

DOI
https://doi.org/10.3389/fendo.2024.1377923
Journal volume & issue
Vol. 15

Abstract

Read online

BackgroundWe explore the effect of suboptimal glycemic control on the incidence of diabetic peripheral neuropathy (DPN) in both non-elderly and elderly patients with type 2 diabetes mellitus (T2DM).MethodsA 6-year follow-up study (2013-2019) enrolled T2DM patients aged >20 without DPN. Participants were classified into two groups: those below 65 years (non-elderly) and those 65 years or older (elderly). Biochemical measurements, including glycated hemoglobin (HbA1C), were recorded regularly. DPN was diagnosed using the Michigan Neuropathy Screening Instrument examination. The outcome was DPN occurrence in 2019.ResultsIn 552 enrollments (69% non-elderly), DPN occurred in 8.4% non-elderly and 24.0% elderly patients. A higher initial HbA1C level was significantly linked with a higher risk of future DPN in the non-elderly group (adjusted odds ratio [AOR] 1.46, 95% CI 1.13–1.89, p=0.004). In comparison, HbA1c at the end of the study period was not associated with DPN in the non-elderly group (AOR 1.17, 95% CI 0.72–1.90, p=0.526). In the elderly group, no statistical relationship was found between HbA1C levels and DPN, either in 2013 or in 2019.ConclusionSuboptimal glycemic control at baseline, rather than at the end of the study period, predicts an increased risk of future DPN in individuals with T2DM under age 65. This correlation is not seen in elderly patients. Therefore, we recommend implementing enhanced glycemic control early in middle-aged T2DM patients and propose individualized therapeutic strategies for diabetes in different age groups.

Keywords